首页> 外文期刊>Frontiers in Immunology >Gut Microbiota Dysbiosis Drives and Implies Novel Therapeutic Strategies for Diabetes Mellitus and Related Metabolic Diseases
【24h】

Gut Microbiota Dysbiosis Drives and Implies Novel Therapeutic Strategies for Diabetes Mellitus and Related Metabolic Diseases

机译:肠道菌群失调驱动并暗示了糖尿病和相关代谢疾病的新型治疗策略

获取原文
获取外文期刊封面目录资料

摘要

Accumulating evidence over the past decade has linked the development of metabolic syndrome related to diabetes to variations in gut microbiota, an emerging, critical homeostatic regulator of host energy metabolism and immune responses. Mechanistic studies in rodent models have revealed an ever-increasing multitude of molecular mechanisms whereby the gut microbiota interacts with various host sensing and signaling pathways, leading to modulation of endocrine system, immune responses, nervous system activity, and hence, the predisposition to metabolic diseases. Remarkably, the microbiota-driven immune responses in metabolic tissues and the host nutrient-sensing mechanisms of gut microbial metabolites, in particular short-chain fatty acids, have been significantly associated with the proneness to diabetes and related disorders. This review will synthesize the recent efforts on unraveling the mediating role of gut microbiota in the pathogenesis of metabolic diseases, aiming to reveal new therapeutic opportunities.
机译:在过去的十年中,越来越多的证据将与糖尿病有关的代谢综合征的发展与肠道菌群的变化联系起来,肠道菌群是宿主能量代谢和免疫反应的新兴,关键的稳态调节器。在啮齿动物模型中进行的机理研究表明,越来越多的分子机制使肠道菌群与各种宿主的传感和信号传导途径相互作用,从而导致内分泌系统,免疫反应,神经系统活动的调节,从而导致代谢疾病的易感性。值得注意的是,代谢组织中微生物群驱动的免疫反应以及肠道微生物代谢产物(尤其是短链脂肪酸)的宿主营养传感机制与糖尿病和相关疾病的易感性密切相关。这篇综述将综合最近在阐明肠道菌群在代谢性疾病发病机理中的介导作用的努力,以揭示新的治疗机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号